Soleno Therapeutics, Inc. (FRA:6XC)
Germany
· Delayed Price · Currency is EUR | Market Cap | 2.37B |
| Revenue (ttm) | 84.10M |
| Net Income (ttm) | -66.86M |
| Shares Out | n/a |
| EPS (ttm) | -1.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 90 |
| Average Volume | 450 |
| Open | 45.00 |
| Previous Close | 45.04 |
| Day's Range | 45.00 - 45.00 |
| 52-Week Range | 36.56 - 76.65 |
| Beta | n/a |
| RSI | 52.69 |
| Earnings Date | Feb 27, 2026 |
About Soleno Therapeutics
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwoo... [Read more]
News
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet?
Connecticut-based fund Braidwell bought nearly 1.3 million shares in Soleno Therapeutics during the third quarter. As a result, the net position change from quarter to quarter was about $86.7 million.
Soleno Therapeutics Announces the Passing of Board Member William G. Harris
REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...
Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advis...
Soleno Therapeutics (SLNO) Initiates Coverage with Outperform Rating | SLNO Stock News
Soleno Therapeutics (SLNO) Initiates Coverage with Outperform Rating | SLNO Stock News
Commit To Buy Soleno Therapeutics At $30, Earn 20.1% Annualized Using Options
Investors considering a purchase of Soleno Therapeutics Inc (Symbol: SLNO) stock, but cautious about paying the going market price of $47.38/share, might benefit from considering selling puts among th...
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Soleno Therapeutics, Inc. (NASDAQ: SLNO) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
NEWTOWN, Pa., Nov. 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Soleno Therapeutics, Inc. (“Soleno” ...
SLNO INVESTIGATION ALERT: Investigation Launched into Soleno Therapeutics, Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - RGRD Law
SAN DIEGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Soleno Therapeutics, Inc. ...
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% – Hagens Berman
SAN FRANCISCO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) saw the price of their shares tumble $18.78 (-28%) after the company reported disappointing infor...
Soleno Therapeutics, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Soleno Therapeutics, Inc., (“Soleno" or the "Company") (NASDAQ: SLNO) investors that the firm has initiated an investigation...
Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses
SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors...
Soleno Therapeutics Unveils $100 Million Buyback Citing 'Underappreciated' Future
Soleno Therapeutics Inc. (NASDAQ: SLNO) stock rose Tuesday after the company said its board had approved a share repurchase program and entered into a $100 million accelerated share repurchase (ASR) ...
Soleno Therapeutics announces entry into $100M accelerated share repurchase agreement
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement
REDWOOD CITY, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare disease...
SLNO INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Soleno Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm
SAN DIEGO--(BUSINESS WIRE)--This is an is investigation into potential violations of U.S. federal securities laws involving Soleno Therapeutics, Inc.
SLNO INVESTIGATION ALERT: Investigation Launched into Soleno Therapeutics, Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
SAN DIEGO , Nov. 7, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Soleno Therapeutics, Inc. (NASDAQ: SLNO) focus...
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKATÔ XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman
SLNO Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , Nov. 7, 2025 /PRNewswire/ -- On November 5, 2025, investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) saw the price of ...
Soleno Therapeutics (SLNO) Shares Drop Despite Beating Q3 Expectations
Soleno Therapeutics (SLNO) Shares Drop Despite Beating Q3 Expectations
Soleno Therapeutics (SLNO) Shares Plummet Over 29%
Soleno Therapeutics (SLNO) Shares Plummet Over 29%
Soleno Therapeutics (SLNO) Shares Drop Significantly
Soleno Therapeutics (SLNO) Shares Drop Significantly
Soleno Therapeutics (SLNO) Achieves Profitability in Q3 2025
Soleno Therapeutics (SLNO) Achieves Profitability in Q3 2025
Soleno Therapeutics, Inc. (SLNO) Q3 2025 Earnings Call Transcript
Decoding Soleno Therapeutics Inc (SLNO): A Strategic SWOT Insight
Decoding Soleno Therapeutics Inc (SLNO): A Strategic SWOT Insight
Soleno Therapeutics Inc (SLNO) Q3 2025 Earnings Call Highlights: Profitability Achieved Amidst ...
Soleno Therapeutics Inc (SLNO) Q3 2025 Earnings Call Highlights: Profitability Achieved Amidst Challenges
Q3 2025 Soleno Therapeutics Inc Earnings Call Transcript
Q3 2025 Soleno Therapeutics Inc Earnings Call Transcript